21st September 2021 | Pharma Updates
Students from Dakshina Kannada perform well in KCET
In the list of Top 10 position holders in BVSc, B. Pharma, D.Pharma, B.sc Agriculture and Bachelor of Naturopathy and Yogic Sciences candidates from the coastal district have secured nine ranks.
Make in India to boost four times growth in biosimilars and vaccines in 2026: Report
The Confederation of Indian Industry in collaboration with Kearney published a report named “Taking India’s life science to the global stage: Make in India to boost four times growth in biosimilars and vaccines by 2026.”
Meet Scientist Murali Divi: Failed 12th exam twice but is now worth more than Rs 72000 cr
Murali Divi had gone to the United States of America with USD 7, and he is now the highest-paid pharma executive.
Alkem Labs closes its Himachal facility
Alkem Labs Board has approved the closure of operations at Beta Block (Unit II) manufacturing facility located at Baddi, HP.
Mirati drug combination reduces tumours in 39% of colon cancer patients
Adagrasib targets KRAS that is present in around 13% of non-small cell lung cancers, 3% to 5% of colorectal cancers and up to 2% of other solid tumours cancers.
Majority of medical doctors in Assam don’t prescribe generic drugs
The majority of doctors in Assam don’t prescribe generic drugs, consequently constraining patients to buy branded drugs.
India will get its first J&J COVID vaccine doses in October
Central Drugs Standard Control Organisation gave emergency authorisation to the Covid-19 vaccine in August.
